An officer of BeOne Medicines Ltd filed a Form 144 notice of proposed sale on November 19, 2026, disclosing plans to sell 2,895 American Depositary Shares acquired through the exercise of stock options.

Key Highlights

  • Proposed sale: Chan Lee, an officer of BeOne Medicines Ltd, proposes to sell 2,895 ADS with an aggregate market value of $1,168,422.00.
  • Acquisition method: The 2,895 ADS were acquired on November 19, 2026, through the exercise of stock options granted by the issuer, with payment made in cash.
  • Exchange and outstanding shares: The ADS trade on NASDAQ; total shares outstanding are reported as 58,926,111.
  • Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, is named as the broker for the proposed sale.
  • Prior sales under 10b5-1 plan: Chan Lee sold 1,115 ADS on November 5, 2026, for gross proceeds of $446,909.95, and 1,115 ADS on September 30, 2026, for gross proceeds of $418,125.00.
  • Trading plan date: The Rule 10b5-1 plan underlying these transactions was adopted on May 29, 2026, according to the filing.

Chan Lee's Proposed ADS Sale at BeOne Medicines

According to the Form 144 filed with the U.S. Securities and Exchange Commission, Chan Lee, an officer of BeOne Medicines Ltd (NASDAQ:ONC as referenced on the filing's securities exchange line showing NASDAQ), proposes to sell 2,895 ADS with an aggregate market value of $1,168,422.00. The approximate date of sale listed in the filing is November 19, 2026. BeOne Medicines Ltd is headquartered at Aeschengraben 27, Basel, Switzerland, 4051, and its SEC file number is listed as 001-37686.

The filing discloses that the 2,895 ADS subject to the proposed sale were acquired on November 19, 2026, through the exercise of stock options issued by the issuer, with the acquisition date and payment date both listed as November 19, 2026, and payment described as cash. The total number of shares or other units outstanding is reported as 58,926,111 in the filing.

The filing also reports two prior sales by Chan Lee under a Rule 10b5-1 plan during the past three months: 1,115 ADS sold on November 5, 2026, with gross proceeds of $446,909.95, and 1,115 ADS sold on September 30, 2026, with gross proceeds of $418,125.00. The date of plan adoption or giving of instruction under Rule 10b5-1 is stated as May 29, 2026. The notice was dated November 19, 2026, and signed by Chan Lee.

What Was Disclosed

BeOne Medicines Ltd officer Chan Lee filed a Form 144 on November 19, 2026, proposing to sell 2,895 ADS valued at $1,168,422.00, acquired via stock option exercise, with two prior 10b5-1 plan sales totaling 2,230 ADS reported in the preceding three months.